LBA59 First-line nivolumab (NIVO) + ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from CheckMate 9LA

Nsclc Patient ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Platinum Based Chemotherapy ◽

93P Patient-reported outcomes (PROs) with cemiplimab or placebo plus platinum-doublet chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 3 trial

Annals of Oncology ◽

10.1016/j.annonc.2021.10.111 ◽

2021 ◽

Vol 32 ◽

pp. S1414

Author(s):

T. Makharadze ◽

R.G. Quek ◽

T. Melkadze ◽

M. Gogishvili ◽

C. Ivanescu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Patient Reported ◽

Doublet Chemotherapy ◽

Platinum Doublet

Nivolumab (Nivo) + Ipilimumab (Ipi) vs Platinum-Doublet Chemotherapy (Chemo) as First-line (1L) Treatment (Tx) for Advanced Non-Small Cell Lung Cancer (NSCLC): Safety Analysis and Patient-Reported Outcomes (PROs) From CheckMate 227.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.9020 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 9020-9020 ◽

Cited By ~ 4

Author(s):

Martin Reck ◽

Matthew David Hellmann ◽

Luis G. Paz-Ares ◽

Suresh S. Ramalingam ◽

Julie R. Brahmer ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Patient Reported ◽

Doublet Chemotherapy ◽

Platinum Doublet

Crizotinib vs platinum‐based chemotherapy as first‐line treatment for advanced non‐small cell lung cancer with different ROS1 fusion variants

Cancer Medicine ◽

10.1002/cam4.2984 ◽

2020 ◽

Vol 9 (10) ◽

pp. 3328-3336 ◽

Cited By ~ 3

Author(s):

Haiyan Xu ◽

Quan Zhang ◽

Li Liang ◽

Junling Li ◽

Zhefeng Liu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Platinum Based Chemotherapy ◽

First Line Treatment

Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours

ESMO Open ◽

10.1016/j.esmoop.2021.100113 ◽

2021 ◽

Vol 6 (3) ◽

pp. 100113

Author(s):

L. Paz-Ares ◽

F. Barlesi ◽

S. Siena ◽

M.-J. Ahn ◽

A. Drilon ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Small Cell ◽

Solid Tumours ◽

Small Cell Lung ◽

138PD_PR Patient-reported outcomes (PROs) in ALEX: A phase III study of alectinib (ALEC) vs crizotinib (CRIZ) in non-small-cell lung cancer (NSCLC)

Journal of Thoracic Oncology ◽

10.1016/s1556-0864(18)30412-x ◽

2018 ◽

Vol 13 (4) ◽

pp. S80-S81 ◽

Cited By ~ 1

Author(s):

M. Perol ◽

S. Peters ◽

N. Pavlakis ◽

E. Levchenko ◽

M. Platania ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Patient Reported ◽

Phase Iii Study

Correlation of C-Reactive Protein with Survival and Radiographic Response to First-Line Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer

Oncology Research and Treatment ◽

10.1159/000165054 ◽

2008 ◽

Vol 31 (12) ◽

pp. 665-670 ◽

Cited By ~ 12

Author(s):

Stefan Wilop ◽

Martina Crysandt ◽

Michael Bendel ◽

Andreas H. Mahnken ◽

Reinhard Osieka ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

C Reactive Protein ◽

Small Cell Lung ◽

First Line ◽

Reactive Protein ◽

Radiographic Response ◽

Platinum Based Chemotherapy

Effect of Smokıng Status on Hematologıcal Toxıcıtıes and Effectıveness of Fırst-Lıne Platınum Based Chemotherapy Admınıstered to Patıents wıth Non-Small Cell Lung Cancer

Eurasian Journal of Medical Investigation ◽

10.14744/ejmi.2021.37729 ◽

2021 ◽

Author(s):

Nilay Sengul Samanci

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Smoking Status ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Platinum Based Chemotherapy

HSR21-067: What Patient-Reported Outcomes Are Being Used in Non-small Cell Lung Cancer? A Targeted Literature Review of Randomized Clinical Trials and Regulatory Labeling

Journal of the National Comprehensive Cancer Network ◽

10.6004/jnccn.2020.7726 ◽

2021 ◽

Vol 19 (3.5) ◽

pp. HSR21-067

Author(s):

Kajal Patel ◽

Soham Shukla ◽

Jennifer Hanlon ◽

Kelly Bell ◽

Laurie Eliason ◽

...

Keyword(s):

Lung Cancer ◽

Clinical Trials ◽

Literature Review ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Randomized Clinical Trials ◽

Small Cell ◽

Small Cell Lung ◽

Abstract 1669: Immunometabolism of circulating neutrophils in hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) alone or in combination with platinum-based chemotherapy (PCT) in non-small cell lung cancer (NSCLC) patients (pts)

10.1158/1538-7445.am2021-1669 ◽

2021 ◽

Author(s):

Roberto Ferrara ◽

Elena Jachetti ◽

Giuseppina Calareso ◽

Marta Brambilla ◽

Giuseppe Lo Russo ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Platinum Based Chemotherapy ◽

Hyperprogressive Disease ◽

Nsclc Patients

Early Postoperative Patient-Reported Outcomes After Thoracoscopic Segmentectomy Versus Lobectomy for Small-Sized Peripheral Non-small-cell Lung Cancer

Annals of Surgical Oncology ◽

10.1245/s10434-021-10946-7 ◽

2021 ◽

Author(s):

Wei Dai ◽

Shuai Chang ◽

Cecilia Pompili ◽

Bin Qiu ◽

Xing Wei ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Postoperative Patient ◽